Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (FGEN) – Get Report on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 6, 2021, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (‘CKD’).” Specifically, the Company stated that the safety analyses “included post-hoc changes to the stratification factors.” FibroGen further revealed that, based on analyses using the pre-specified stratification factors, the Company “cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.”
On this news, the Company’s share price declined by $14.90 per share, or approximately 43%, to close at $19.74 per share on April 7, 2021.
If you purchased or otherwise acquired FibroGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005754/en/
————————
Originally published at https://www.thestreet.com/press-releases/fibrogen-alert-bragar-eagel-amp-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm-15619223 on .
